01 July 1999
Comparison of different groups of cholesterol lowering drugs and total mortality: a meta-analysis
Adam SternoMed Sci Monit 1999; 5(4): SR786-793 :: ID: 504675
Abstract
Introduction: The aim of this study was to compare different groups of cholesterol lowering drugs. Material: Randomized trials were included if: (1) they lasted for 2 years or more, (2) the intention to treat total mortality data was obtainable, (3) at least one death had occurred, (4) one cholesterol lowering drug (fibrate, nicotinic acid and its derivate acipimox, resin, statin or probucol) was used, (5) they were published before the end of 1997. Computerized database (MEDLINE), references from former meta-analyses, overviews and already located trials were the source of data. Method: Meta-analysis. We used the conventional pooled odds ratio (OR) method. OR was calculated for each drug and for each group of drugs. Results: 26 trials were included. Out of all drug groups the total mortality only decreased amongst statins OR=0.76 (95% CI 0.68-0.86). Fibrates OR=1.08 (95% CI 0.97Ð1.21), nicotinic acid together with acipimox OR=0.94 (95% CI 0.81-1.09), resins OR=0.86 (95% CI 0.66-1.11) had no effect on the total mortality. We found no trials with probucol. Similar results were obtained following an additional analysis using the same methods and involving trials with the percentage of patients with unknown vital conditions (5% and no cholestyramine. These conclusions could only be valid in the case of patients with hypercholesterolemia and mixed hyperlipidemia with only moderately elevated triglyceride levels. Randomized, long term trials did not involve patients with hypertriglyceridemia and mixed hyperlipidemia with considerably elevated triglyceride levels. Conclusions: There exists a difference in the total mortality between different groups of cholesterol lowering drugs. Only statins lowered the total mortality.
Keywords: Mortality, cholesterol lowering drugs, cholesterol level
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952